Teva and Samsung Bioepis Launch Epysqli (Biosimilar, Soliris) in the US
Shots:
- Teva & Samsung Bioepis have launched Epysqli, a biosimilar version of Soliris (eculizumab) in the US to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) & generalized myasthenia gravis (gMG) in AchR antibody-positive adults
- Epysqli was approved by the US FDA in Jul 2024 for PNH & aHUS, with a label expansion to gMG in Nov 2024 & was also granted interchangeability designation by the FDA
- In Jan 2025, Samsung Bioepis & Teva have entered into a collaboration to commercialize Epysqli in the US market, with Samsung handling development, manufacturing, & supply, whereas Teva would handle commercialization
Ref: Teva | Image: Teva & Samsung Bioepis
Related News:- Teva Pharmaceuticals Reports the US FDA’s sBLA Acceptance of Ajovy (Fremanezumab) for Pediatric Episodic Migraine Prevention
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
